---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-266842"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:09:57.560722+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q3 net loss $306M; aficamten PDUFA on track; raises $750M convertible notes

## Summary
- Q3 net loss $306.2M ($2.55/share) vs $160.5M loss in prior year; includes $121.2M debt conversion expense.
- Cash, cash equivalents & investments $1.25B at Sep 30; raised $750M 1.75% convertible notes due 2031, used $402.5M to retire $399.5M of 2027 notes.
- PDUFA date for aficamten NDA remains Dec 26, 2025; commercial launch preparations on track.
- Updated FY2025 GAAP operating expense guidance to $680M-$700M (prior $670M-$710M).
- Total Q3 revenue $1.9M (vs $0.5M); R&D $99.2M, G&A $69.5M.

## SEC filing metadata
- accession: 0001193125-25-266842
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/0001193125-25-266842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-266842
- JSON: https://secwatch.observer/filing/0001193125-25-266842.json
- Plain text: https://secwatch.observer/filing/0001193125-25-266842.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.